Treatment of femoral fracture nonunion after long-term bisphosphonate use

Orthopedics

Volumn 35, Issue 6, 2012, Pages

  Grady, Mary K ^a   Watson, J Tracy ^a   Cannada, Lisa K ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GABAPENTIN; RANITIDINE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BISPHOSPHONATE FRACTURE; BONE GRAFT; CASE REPORT; CHRONIC DRUG ADMINISTRATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BREAKING; DEVICE REMOVAL; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; FALLING; FEMALE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; FRACTURE NONUNION; FRACTURE RISK; HIGH RISK PATIENT; HIP RADIOGRAPHY; HUMAN; HYSTERECTOMY; INTRAMEDULLARY NAILING; KNEE PAIN; LEG PAIN; METABOLIC BONE DISEASE; MUSCLE WEAKNESS; OPEN REDUCTION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; STRESS FRACTURE; TRANSVERSE FRACTURE; TREATMENT FAILURE; VARUS DEFORMITY;

ADULT; BONE DENSITY CONSERVATION AGENTS; BONE PLATES; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTERNAL; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURE HEALING; FRACTURES, MALUNITED; HUMANS; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84864643434     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20120525-51     Document Type: Article

References (20)

1. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25(11):2267-2294.
2. Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009; 467:1921-1926.
3. Goh SK, Yang KY, Koh JSB, et al. Subtrocanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89(3):349-353. (Pubitemid 46563912)
4. Capeci CM, Tejwani NC. Bilateral lowenergy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009; 91:2556-2561.
5. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-350. (Pubitemid 351630250)
6. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010; 92(5):679-686.
7. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthopaedica. 2009; 80(4):413-415.
8. Schneider, JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009; 64(1):18-23.
9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294-1301. (Pubitemid 40463979)
10. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008; 39(2):224-231.
11. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in post-menopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-1306. (Pubitemid 351439247)
12. Goddard MS, Reid KR, Johnston JC, Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009; 32(8):607-610.
13. Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone. 2011; 49(1):82-88.
14. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535-1541. (Pubitemid 26411651)
15. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-1199. (Pubitemid 38339363)
16. Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011; 49(1):2-19.
17. Black DM, Kelly MP, Genant HK, et al. Fracture Intervention Trial Steering Committee; Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362(19):1761-1771.
18. Pasala S, Burshell A, Ogden F. Long-term alendronate therapy and subtrochanteric femoral fractures. Ochsner J. 2010; 10(1):22.
19. Food and Drug Administration. FDA Drug Safety Communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Author's Web site. http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm. Published October 13, 2010. Accessed May 22, 2012.
20. Norris R, Bhattacharjee D, Parker MJ. Occurrence of secondary fracture around intramedullary nails used for trochanteric hip fractures: a systematic review of 13,568 patients [published online ahead of print December 3, 2011]. Injury. 2012; 43(6):706-711.